 | • レポートコード：D0804-06509 • 出版社/出版日：GlobalInfoResearch / 2020年7月28日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、102ページ • 納品方法：Eメール • 産業分類：医薬品・治療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、関節リウマチ薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。関節リウマチ薬の種類別市場規模（処方箋、OTC）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：AbbVie Inc、Mitsubishi Tanabe Pharma Corp、Pfizer Inc、Hoffman-La Roche AG、UCB Biosciences Inc、Amgen Inc、Merck & Co、Johnson & Johnson、Bristol-Myers Squibb Co、Biogen Inc、Market Segment by Product Type、Pharmaceuticals、Biopharmaceuticals ・地域別グローバル市場分析 2015年-2020年 ・関節リウマチ薬の北米市場（アメリカ、カナダ、メキシコ） ・関節リウマチ薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・関節リウマチ薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・関節リウマチ薬の南米市場（ブラジル、アルゼンチン） ・関節リウマチ薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：処方箋、OTC ・用途別分析：病院、クリニック、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Drugs for Rheumatoid Arthritis market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.5% in the forecast period of 2020 to 2025 and will expected to reach USD 23310 million by 2025, from USD 20320 million in 2019.
The Drugs for Rheumatoid Arthritis market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Drugs for Rheumatoid Arthritis market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Drugs for Rheumatoid Arthritis market has been segmented into
Prescription
OTC
By Application, Drugs for Rheumatoid Arthritis has been segmented into:
Hospital
Clinics
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Drugs for Rheumatoid Arthritis market presented in the report. This section sheds light on the sales growth of different regional and country-level Drugs for Rheumatoid Arthritis markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Drugs for Rheumatoid Arthritis market.
The report offers in-depth assessment of the growth and other aspects of the Drugs for Rheumatoid Arthritis market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Drugs for Rheumatoid Arthritis Market Share Analysis
Drugs for Rheumatoid Arthritis competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Drugs for Rheumatoid Arthritis sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Drugs for Rheumatoid Arthritis sales, revenue and market share for each player covered in this report.
The major players covered in Drugs for Rheumatoid Arthritis are:
AbbVie Inc
Mitsubishi Tanabe Pharma Corp
Pfizer Inc
Hoffman-La Roche AG
UCB Biosciences Inc
Amgen Inc
Merck & Co
Johnson & Johnson
Bristol-Myers Squibb Co
Biogen Inc
Market Segment by Product Type
Pharmaceuticals
Biopharmaceuticals
Among other players domestic and global, Drugs for Rheumatoid Arthritis market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Rheumatoid Arthritis product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for Rheumatoid Arthritis, with price, sales, revenue and global market share of Drugs for Rheumatoid Arthritis in 2018 and 2019.
Chapter 3, the Drugs for Rheumatoid Arthritis competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Rheumatoid Arthritis breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Drugs for Rheumatoid Arthritis market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Drugs for Rheumatoid Arthritis sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Drugs for Rheumatoid Arthritis Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drugs for Rheumatoid Arthritis Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Prescription
1.2.3 OTC
1.3 Market Analysis by Application
1.3.1 Overview: Global Drugs for Rheumatoid Arthritis Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Overview of Global Drugs for Rheumatoid Arthritis Market
1.4.1 Global Drugs for Rheumatoid Arthritis Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AbbVie Inc
2.1.1 AbbVie Inc Details
2.1.2 AbbVie Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AbbVie Inc SWOT Analysis
2.1.4 AbbVie Inc Product and Services
2.1.5 AbbVie Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Mitsubishi Tanabe Pharma Corp
2.2.1 Mitsubishi Tanabe Pharma Corp Details
2.2.2 Mitsubishi Tanabe Pharma Corp Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Mitsubishi Tanabe Pharma Corp SWOT Analysis
2.2.4 Mitsubishi Tanabe Pharma Corp Product and Services
2.2.5 Mitsubishi Tanabe Pharma Corp Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Pfizer Inc
2.3.1 Pfizer Inc Details
2.3.2 Pfizer Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Pfizer Inc SWOT Analysis
2.3.4 Pfizer Inc Product and Services
2.3.5 Pfizer Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Hoffman-La Roche AG
2.4.1 Hoffman-La Roche AG Details
2.4.2 Hoffman-La Roche AG Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Hoffman-La Roche AG SWOT Analysis
2.4.4 Hoffman-La Roche AG Product and Services
2.4.5 Hoffman-La Roche AG Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 UCB Biosciences Inc
2.5.1 UCB Biosciences Inc Details
2.5.2 UCB Biosciences Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 UCB Biosciences Inc SWOT Analysis
2.5.4 UCB Biosciences Inc Product and Services
2.5.5 UCB Biosciences Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Amgen Inc
2.6.1 Amgen Inc Details
2.6.2 Amgen Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Amgen Inc SWOT Analysis
2.6.4 Amgen Inc Product and Services
2.6.5 Amgen Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Merck & Co
2.7.1 Merck & Co Details
2.7.2 Merck & Co Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Merck & Co SWOT Analysis
2.7.4 Merck & Co Product and Services
2.7.5 Merck & Co Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Johnson & Johnson
2.8.1 Johnson & Johnson Details
2.8.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Johnson & Johnson SWOT Analysis
2.8.4 Johnson & Johnson Product and Services
2.8.5 Johnson & Johnson Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Bristol-Myers Squibb Co
2.9.1 Bristol-Myers Squibb Co Details
2.9.2 Bristol-Myers Squibb Co Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Bristol-Myers Squibb Co SWOT Analysis
2.9.4 Bristol-Myers Squibb Co Product and Services
2.9.5 Bristol-Myers Squibb Co Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Biogen Inc
2.10.1 Biogen Inc Details
2.10.2 Biogen Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Biogen Inc SWOT Analysis
2.10.4 Biogen Inc Product and Services
2.10.5 Biogen Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Market Segment by Product Type
2.11.1 Market Segment by Product Type Details
2.11.2 Market Segment by Product Type Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Market Segment by Product Type SWOT Analysis
2.11.4 Market Segment by Product Type Product and Services
2.11.5 Market Segment by Product Type Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Pharmaceuticals
2.12.1 Pharmaceuticals Details
2.12.2 Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Pharmaceuticals SWOT Analysis
2.12.4 Pharmaceuticals Product and Services
2.12.5 Pharmaceuticals Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 Biopharmaceuticals
2.13.1 Biopharmaceuticals Details
2.13.2 Biopharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Biopharmaceuticals SWOT Analysis
2.13.4 Biopharmaceuticals Product and Services
2.13.5 Biopharmaceuticals Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Drugs for Rheumatoid Arthritis Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Drugs for Rheumatoid Arthritis Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Drugs for Rheumatoid Arthritis Manufacturer Market Share in 2019
3.3.2 Top 6 Drugs for Rheumatoid Arthritis Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Regions
4.1.1 Global Drugs for Rheumatoid Arthritis Sales and Market Share by Regions (2015-2020)
4.1.2 Global Drugs for Rheumatoid Arthritis Revenue and Market Share by Regions (2015-2020)
4.2 North America Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
4.3 Europe Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
4.5 South America Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Country
5.1.1 North America Drugs for Rheumatoid Arthritis Sales and Market Share by Country (2015-2020)
5.1.2 North America Drugs for Rheumatoid Arthritis Revenue and Market Share by Country (2015-2020)
5.2 United States Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
5.3 Canada Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
5.4 Mexico Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Country
6.1.1 Europe Drugs for Rheumatoid Arthritis Sales and Market Share by Country (2015-2020)
6.1.2 Europe Drugs for Rheumatoid Arthritis Revenue and Market Share by Country (2015-2020)
6.2 Germany Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
6.3 UK Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
6.4 France Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
6.5 Russia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
6.6 Italy Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Drugs for Rheumatoid Arthritis Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Drugs for Rheumatoid Arthritis Revenue and Market Share by Regions (2015-2020)
7.2 China Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
7.3 Japan Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
7.4 Korea Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
7.5 India Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
7.7 Australia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Country
8.1.1 South America Drugs for Rheumatoid Arthritis Sales and Market Share by Country (2015-2020)
8.1.2 South America Drugs for Rheumatoid Arthritis Revenue and Market Share by Country (2015-2020)
8.2 Brazil Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
8.3 Argentina Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Drugs for Rheumatoid Arthritis Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Drugs for Rheumatoid Arthritis Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
9.3 Turkey Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
9.4 Egypt Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
9.5 South Africa Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Drugs for Rheumatoid Arthritis Sales and Market Share by Type (2015-2020)
10.2 Global Drugs for Rheumatoid Arthritis Revenue and Market Share by Type (2015-2020)
10.3 Global Drugs for Rheumatoid Arthritis Price by Type (2015-2020)
11 Global Drugs for Rheumatoid Arthritis Market Segment by Application
11.1 Global Drugs for Rheumatoid Arthritis Sales Market Share by Application (2015-2020)
11.2 Global Drugs for Rheumatoid Arthritis Revenue Market Share by Application (2015-2020)
11.3 Global Drugs for Rheumatoid Arthritis Price by Application (2015-2020)
12 Market Forecast
12.1 Global Drugs for Rheumatoid Arthritis Sales, Revenue and Growth Rate (2021-2025)
12.2 Drugs for Rheumatoid Arthritis Market Forecast by Regions (2021-2025)
12.2.1 North America Drugs for Rheumatoid Arthritis Market Forecast (2021-2025)
12.2.2 Europe Drugs for Rheumatoid Arthritis Market Forecast (2021-2025)
12.2.3 Asia-Pacific Drugs for Rheumatoid Arthritis Market Forecast (2021-2025)
12.2.4 South America Drugs for Rheumatoid Arthritis Market Forecast (2021-2025)
12.2.5 Middle East & Africa Drugs for Rheumatoid Arthritis Market Forecast (2021-2025)
12.3 Drugs for Rheumatoid Arthritis Market Forecast by Type (2021-2025)
12.3.1 Global Drugs for Rheumatoid Arthritis Sales Forecast by Type (2021-2025)
12.3.2 Global Drugs for Rheumatoid Arthritis Market Share Forecast by Type (2021-2025)
12.4 Drugs for Rheumatoid Arthritis Market Forecast by Application (2021-2025)
12.4.1 Global Drugs for Rheumatoid Arthritis Sales Forecast by Application (2021-2025)
12.4.2 Global Drugs for Rheumatoid Arthritis Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Drugs for Rheumatoid Arthritis Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Drugs for Rheumatoid Arthritis by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Drugs for Rheumatoid Arthritis Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. AbbVie Inc Basic Information, Manufacturing Base and Competitors
Table 8. AbbVie Inc Drugs for Rheumatoid Arthritis Major Business
Table 9. AbbVie Inc Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 10. AbbVie Inc SWOT Analysis
Table 11. AbbVie Inc Drugs for Rheumatoid Arthritis Product and Services
Table 12. AbbVie Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Mitsubishi Tanabe Pharma Corp Basic Information, Manufacturing Base and Competitors
Table 14. Mitsubishi Tanabe Pharma Corp Drugs for Rheumatoid Arthritis Major Business
Table 15. Mitsubishi Tanabe Pharma Corp Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 16. Mitsubishi Tanabe Pharma Corp SWOT Analysis
Table 17. Mitsubishi Tanabe Pharma Corp Drugs for Rheumatoid Arthritis Product and Services
Table 18. Mitsubishi Tanabe Pharma Corp Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Inc Drugs for Rheumatoid Arthritis Major Business
Table 21. Pfizer Inc Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 22. Pfizer Inc SWOT Analysis
Table 23. Pfizer Inc Drugs for Rheumatoid Arthritis Product and Services
Table 24. Pfizer Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Hoffman-La Roche AG Basic Information, Manufacturing Base and Competitors
Table 26. Hoffman-La Roche AG Drugs for Rheumatoid Arthritis Major Business
Table 27. Hoffman-La Roche AG Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 28. Hoffman-La Roche AG SWOT Analysis
Table 29. Hoffman-La Roche AG Drugs for Rheumatoid Arthritis Product and Services
Table 30. Hoffman-La Roche AG Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. UCB Biosciences Inc Basic Information, Manufacturing Base and Competitors
Table 32. UCB Biosciences Inc Drugs for Rheumatoid Arthritis Major Business
Table 33. UCB Biosciences Inc Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 34. UCB Biosciences Inc SWOT Analysis
Table 35. UCB Biosciences Inc Drugs for Rheumatoid Arthritis Product and Services
Table 36. UCB Biosciences Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 38. Amgen Inc Drugs for Rheumatoid Arthritis Major Business
Table 39. Amgen Inc Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 40. Amgen Inc SWOT Analysis
Table 41. Amgen Inc Drugs for Rheumatoid Arthritis Product and Services
Table 42. Amgen Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 44. Merck & Co Drugs for Rheumatoid Arthritis Major Business
Table 45. Merck & Co Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 46. Merck & Co SWOT Analysis
Table 47. Merck & Co Drugs for Rheumatoid Arthritis Product and Services
Table 48. Merck & Co Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 50. Johnson & Johnson Drugs for Rheumatoid Arthritis Major Business
Table 51. Johnson & Johnson Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 52. Johnson & Johnson SWOT Analysis
Table 53. Johnson & Johnson Drugs for Rheumatoid Arthritis Product and Services
Table 54. Johnson & Johnson Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Bristol-Myers Squibb Co Basic Information, Manufacturing Base and Competitors
Table 56. Bristol-Myers Squibb Co Drugs for Rheumatoid Arthritis Major Business
Table 57. Bristol-Myers Squibb Co Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 58. Bristol-Myers Squibb Co SWOT Analysis
Table 59. Bristol-Myers Squibb Co Drugs for Rheumatoid Arthritis Product and Services
Table 60. Bristol-Myers Squibb Co Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Biogen Inc Basic Information, Manufacturing Base and Competitors
Table 62. Biogen Inc Drugs for Rheumatoid Arthritis Major Business
Table 63. Biogen Inc Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 64. Biogen Inc SWOT Analysis
Table 65. Biogen Inc Drugs for Rheumatoid Arthritis Product and Services
Table 66. Biogen Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Market Segment by Product Type Basic Information, Manufacturing Base and Competitors
Table 68. Market Segment by Product Type Drugs for Rheumatoid Arthritis Major Business
Table 69. Market Segment by Product Type Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 70. Market Segment by Product Type SWOT Analysis
Table 71. Market Segment by Product Type Drugs for Rheumatoid Arthritis Product and Services
Table 72. Market Segment by Product Type Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 74. Pharmaceuticals Drugs for Rheumatoid Arthritis Major Business
Table 75. Pharmaceuticals Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 76. Pharmaceuticals SWOT Analysis
Table 77. Pharmaceuticals Drugs for Rheumatoid Arthritis Product and Services
Table 78. Pharmaceuticals Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 80. Biopharmaceuticals Drugs for Rheumatoid Arthritis Major Business
Table 81. Biopharmaceuticals Drugs for Rheumatoid Arthritis Total Revenue (USD Million) (2017-2018)
Table 82. Biopharmaceuticals SWOT Analysis
Table 83. Biopharmaceuticals Drugs for Rheumatoid Arthritis Product and Services
Table 84. Biopharmaceuticals Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Global Drugs for Rheumatoid Arthritis Sales by Manufacturer (2018-2019) (K Units)
Table 86. Global Drugs for Rheumatoid Arthritis Revenue by Manufacturer (2018-2019) (USD Million)
Table 87. Global Drugs for Rheumatoid Arthritis Sales by Regions (2015-2020) (K Units)
Table 88. Global Drugs for Rheumatoid Arthritis Sales Market Share by Regions (2015-2020)
Table 89. Global Drugs for Rheumatoid Arthritis Revenue by Regions (2015-2020) (USD Million)
Table 90. North America Drugs for Rheumatoid Arthritis Sales by Countries (2015-2020) (K Units)
Table 91. North America Drugs for Rheumatoid Arthritis Sales Market Share by Countries (2015-2020)
Table 92. North America Drugs for Rheumatoid Arthritis Revenue by Countries (2015-2020) (USD Million)
Table 93. North America Drugs for Rheumatoid Arthritis Revenue Market Share by Countries (2015-2020)
Table 94. Europe Drugs for Rheumatoid Arthritis Sales by Countries (2015-2020) (K Units)
Table 95. Europe Drugs for Rheumatoid Arthritis Sales Market Share by Countries (2015-2020)
Table 96. Europe Drugs for Rheumatoid Arthritis Revenue by Countries (2015-2020) (USD Million)
Table 97. Asia-Pacific Drugs for Rheumatoid Arthritis Sales by Regions (2015-2020) (K Units)
Table 98. Asia-Pacific Drugs for Rheumatoid Arthritis Sales Market Share by Regions (2015-2020)
Table 99. Asia-Pacific Drugs for Rheumatoid Arthritis Revenue by Regions (2015-2020) (USD Million)
Table 100. South America Drugs for Rheumatoid Arthritis Sales by Countries (2015-2020) (K Units)
Table 101. South America Drugs for Rheumatoid Arthritis Sales Market Share by Countries (2015-2020)
Table 102. South America Drugs for Rheumatoid Arthritis Revenue by Countries (2015-2020) (USD Million)
Table 103. South America Drugs for Rheumatoid Arthritis Revenue Market Share by Countries (2015-2020)
Table 104. Middle East & Africa Drugs for Rheumatoid Arthritis Sales by Countries (2015-2020) (K Units)
Table 105. Middle East & Africa Drugs for Rheumatoid Arthritis Sales Market Share by Countries (2015-2020)
Table 106. Middle East & Africa Drugs for Rheumatoid Arthritis Revenue by Countries (2015-2020) (USD Million)
Table 107. Middle East & Africa Drugs for Rheumatoid Arthritis Revenue Market Share by Countries (2015-2020)
Table 108. Global Drugs for Rheumatoid Arthritis Sales by Type (2015-2020) (K Units)
Table 109. Global Drugs for Rheumatoid Arthritis Sales Share by Type (2015-2020)
Table 110. Global Drugs for Rheumatoid Arthritis Revenue by Type (2015-2020) (USD Million)
Table 111. Global Drugs for Rheumatoid Arthritis Revenue Share by Type (2015-2020)
Table 112. Global Drugs for Rheumatoid Arthritis Sales by Application (2015-2020) (K Units)
Table 113. Global Drugs for Rheumatoid Arthritis Sales Share by Application (2015-2020)
Table 114. Global Drugs for Rheumatoid Arthritis Sales Forecast by Regions (2021-2025) (K Units)
Table 115. Global Drugs for Rheumatoid Arthritis Market Share Forecast by Regions (2021-2025)
Table 116. Global Drugs for Rheumatoid Arthritis Sales Forecast by Type (2021-2025) (K Units)
Table 117. Global Drugs for Rheumatoid Arthritis Market Share Forecast by Type (2021-2025)
Table 118. Global Drugs for Rheumatoid Arthritis Sales Forecast by Application (2021-2025)
Table 119. Global Drugs for Rheumatoid Arthritis Market Share Forecast by Application (2021-2025)
Table 120. Direct Channel Pros & Cons
Table 121. Indirect Channel Pros & Cons
Table 122. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Drugs for Rheumatoid Arthritis Picture
Figure 2. Global Sales Market Share of Drugs for Rheumatoid Arthritis by Type in 2019
Figure 3. Prescription Picture
Figure 4. OTC Picture
Figure 5. Drugs for Rheumatoid Arthritis Sales Market Share by Application in 2018
Figure 6. Hospital Picture
Figure 7. Clinics Picture
Figure 8. Other Picture
Figure 9. Global Drugs for Rheumatoid Arthritis Market Status and Outlook (2015-2025) (USD Million)
Figure 10. United States Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 11. Canada Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Mexico Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Germany Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 14. France Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 15. UK Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Russia Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Italy Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 18. China Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Japan Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Korea Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 21. India Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Southeast Asia Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Australia Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 24. Brazil Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Egypt Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Saudi Arabia Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 27. South Africa Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Turkey Drugs for Rheumatoid Arthritis Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Global Drugs for Rheumatoid Arthritis Sales Market Share by Manufacturer in 2019
Figure 30. Global Drugs for Rheumatoid Arthritis Revenue Market Share by Manufacturer in 2019
Figure 31. Top 3 Drugs for Rheumatoid Arthritis Manufacturer (Revenue) Market Share in 2019
Figure 32. Top 6 Drugs for Rheumatoid Arthritis Manufacturer (Revenue) Market Share in 2019
Figure 33. Key Manufacturer Market Share Trend
Figure 34. Global Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 35. Global Drugs for Rheumatoid Arthritis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 36. Global Drugs for Rheumatoid Arthritis Revenue Market Share by Regions (2015-2020)
Figure 37. Global Drugs for Rheumatoid Arthritis Revenue Market Share by Regions in 2018
Figure 38. North America Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
Figure 39. Europe Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
Figure 41. South America Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
Figure 42. Middle East & Africa Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020)
Figure 43. North America Drugs for Rheumatoid Arthritis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 44. North America Drugs for Rheumatoid Arthritis Sales Market Share by Countries (2015-2020)
Figure 45. North America Drugs for Rheumatoid Arthritis Sales Market Share by Countries in 2018
Figure 46. North America Drugs for Rheumatoid Arthritis Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 47. North America Drugs for Rheumatoid Arthritis Revenue Market Share by Countries in 2018
Figure 48. United States Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 49. Canada Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 50. Mexico Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Europe Drugs for Rheumatoid Arthritis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 52. Europe Drugs for Rheumatoid Arthritis Revenue Market Share by Countries (2015-2020)
Figure 53. Europe Drugs for Rheumatoid Arthritis Revenue Market Share by Countries in 2019
Figure 54. Germany Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 55. UK Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 56. France Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 57. Russia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 58. Italy Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Asia-Pacific Drugs for Rheumatoid Arthritis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 60. Asia-Pacific Drugs for Rheumatoid Arthritis Sales Market Share by Regions 2019
Figure 61. Asia-Pacific Drugs for Rheumatoid Arthritis Revenue Market Share by Regions 2019
Figure 62. China Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 63. Japan Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 64. Korea Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 65. India Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Southeast Asia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 67. South America Drugs for Rheumatoid Arthritis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 68. South America Drugs for Rheumatoid Arthritis Sales Market Share by Countries in 2019
Figure 69. South America Drugs for Rheumatoid Arthritis Revenue Market Share by Countries in 2019
Figure 70. Brazil Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 71. Argentina Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 72. Middle East and Africa Drugs for Rheumatoid Arthritis Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. Middle East and Africa Drugs for Rheumatoid Arthritis Sales Market Share by Countries in 2019
Figure 74. Middle East and Africa Drugs for Rheumatoid Arthritis Revenue Market Share by Countries (2015-2020)
Figure 75. Middle East and Africa Drugs for Rheumatoid Arthritis Revenue Market Share by Countries in 2019
Figure 76. Saudi Arabia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 77. Egypt Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 78. Turkey Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 79. South Africa Drugs for Rheumatoid Arthritis Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Global Drugs for Rheumatoid Arthritis Sales and Growth Rate (2021-2025) (K Units)
Figure 81. Global Drugs for Rheumatoid Arthritis Revenue and Growth Rate (2021-2025) (USD Million)
Figure 82. North America Sales Drugs for Rheumatoid Arthritis Market Forecast (2021-2025) (K Units)
Figure 83. Europe Sales Drugs for Rheumatoid Arthritis Market Forecast (2021-2025) (K Units)
Figure 84. Asia-Pacific Sales Drugs for Rheumatoid Arthritis Market Forecast (2021-2025) (K Units)
Figure 85. South America Sales Drugs for Rheumatoid Arthritis Market Forecast (2021-2025) (K Units)
Figure 86. Middle East & Africa Sales Drugs for Rheumatoid Arthritis Market Forecast (2021-2025) (K Units)
Figure 87. Sales Channel: Direct Channel vs Indirect Channel
乾癬性関節炎治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Psoriatic Arthritis Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Psoriatic Arthritis…- 関節リウマチ治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Rhematoid Arthritis Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Rhematoid Arthritis…
- 血漿由来薬物の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Plasma Derived Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Plasma Derived Drugs mar…
- 腎臓用治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Renal Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…
- アンチエイジング薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Anti-Ageing Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 7.2% in the forecast period of 2020 to 2025 and will expected to reach USD 106360 million by 2025, from USD 80490 million in 2019. The Anti-Ageing Drugs m…